Pharmacogenetics of nevirapine-associated hepatotoxicity: An adult AIDS clinical trials group collaboration

被引：97

作者：

Haas, David W.

Bartlett, John A.

Andersen, Janet W.

Sanne, Ian

Wilkinson, Grant R.

Hinkle, John

Rousseau, Franck

Ingram, Christiana D.

Shaw, Audrey

Lederman, Michael M.

Kim, Richard B.

机构：

[1] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37203 USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] Gilead Sci Inc, Durham, NC USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[5] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA

[6] Univ Witwatersrand, Johannesburg, South Africa

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 43卷 / 06期

关键词：

D O I：

10.1086/507097

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa ( FTC-302), MDR1 3435C -> T was significantly associated with decreased risk of hepatotoxicity ( risk ratio, 0.30; P = .016).

引用

收藏

页码：783 / 786

页数：4

相关论文

共 11 条

[1] Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals [J].

Almond, LM ;

Edirisinghe, D ;

Dalton, M ;

Bonington, A ;

Back, DJ ;

Khoo, SH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :132-142

[2] Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo [J].

Colombo, S ;

Soranzo, N ;

Rotger, M ;

Sprenger, R ;

Bleiber, G ;

Furrer, H ;

Buclin, T ;

Goldstein, D ;

Décosterd, L ;

Telenti, A .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) :599-608

[3] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].

Fellay, J ;

Marzolini, C ;

Meaden, ER ;

Back, DJ ;

Buclin, T ;

Chave, JP ;

Decosterd, LA ;

Furrer, H ;

Opravil, M ;

Pantaleo, G ;

Retelska, D ;

Ruiz, L ;

Schinkel, AH ;

Vernazza, P ;

Eap, CB ;

Telenti, A .

LANCET, 2002, 359 (9300) :30-36

[4] Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study [J].

Haas, DW ;

Smeaton, LM ;

Shafer, RW ;

Robbins, GK ;

Morse, GD ;

Labbé, L ;

Wilkinson, GR ;

Clifford, DB ;

D'Aquila, RT ;

De Gruttola, V ;

Pollard, RB ;

Merigan, TC ;

Hirsch, MS ;

George, AL ;

Donahue, JP ;

Kim, RB .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) :1931-1942

[5]

Haas DW, 2004, AIDS, V18, P2391

[6] Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts [J].

Martin, AM ;

Nolan, D ;

James, I ;

Cameron, P ;

Keller, J ;

Moore, C ;

Phillips, E ;

Christiansen, FT ;

Mallal, S .

AIDS, 2005, 19 (01) :97-99

[7] Polymorphisms in human MDR1 (P-glycoprotein):: Recent advances and clinical relevance [J].

Marzolini, C ;

Paus, E ;

Buclin, T ;

Kim, RB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (01) :13-33

[8] Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity [J].

Ritchie, Marylyn D. ;

Haas, David W. ;

Motsinger, Alison A. ;

Donahue, John P. ;

Erdem, Huso ;

Raffanti, Stephen ;

Rebeiro, Peter ;

George, Alfred L. ;

Kim, Richard B. ;

Haines, Jonathan L. ;

Sterling, Timothy R. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (06) :779-782

[9] Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects [J].

Sanne, I ;

Mommeja-Marin, H ;

Hinkle, J ;

Bartlett, JA ;

Lederman, MM ;

Maartens, G ;

Wakeford, C ;

Shaw, A ;

Quinn, J ;

Gish, RG ;

Rousseau, F .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06) :825-829

[10] Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture [J].

Störmer, E ;

von Moltke, LL ;

Perloff, MD ;

Greenblatt, DJ .

PHARMACEUTICAL RESEARCH, 2002, 19 (07) :1038-1045